List of Excipients in Branded Drug LAPATINIB

Generic Drugs Containing LAPATINIB

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	lapatinib	0480-3237	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals Inc	lapatinib	0480-3237	FERRIC OXIDE YELLOW
Teva Pharmaceuticals Inc	lapatinib	0480-3237	MAGNESIUM STEARATE
Teva Pharmaceuticals Inc	lapatinib	0480-3237	POLYETHYLENE GLYCOL 3350
Teva Pharmaceuticals Inc	lapatinib	0480-3237	POLYVINYL ALCOHOL

What are the Most Frequently-Used Excipients in LAPATINIB?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	FD&C YELLOW NO. 6
2	FERRIC OXIDE YELLOW
1	HYPROMELLOSE
1	LECITHIN, SOYBEAN

Lapatinib Excipient Strategy and Commercial Opportunities

Last updated: July 31, 2026

Lapatinib is an orally administered, poorly water-soluble kinase inhibitor whose commercial formulation value is concentrated in dissolution control, food-effect management, tablet robustness, and manufacturability. The reference product, Tykerb/Tyverb, uses a conventional immediate-release tablet with lapatinib ditosylate monohydrate and standard excipients. Its composition leaves room for generic manufacturers and specialty developers to compete through bioequivalence, lower-cost processing, improved tablet performance, and differentiated delivery systems rather than through biosimilar development.

What formulation is used for lapatinib?

Tykerb contains lapatinib ditosylate monohydrate, equivalent to 250 mg of lapatinib per tablet. The reference product is supplied as 250 mg tablets, with a recommended dose of 1,250 mg once daily when used with capecitabine or 1,500 mg once daily when used with an aromatase inhibitor.[1]

The labeled inactive ingredients include:

Formulation element	Reference-product role
Microcrystalline cellulose	Diluent and compression aid
Povidone	Binder
Sodium starch glycolate	Superdisintegrant
Magnesium stearate	Lubricant
Film-coating materials	Color, protection and swallowability

The reference formulation is an immediate-release, high-dose tablet. Five 250 mg tablets are required for the 1,250 mg daily regimen, increasing tablet burden, packaging volume and exposure to excipient variability.

What is the active pharmaceutical ingredient?

Lapatinib is administered as the ditosylate monohydrate salt. The salt improves handling and enables tablet manufacture, but lapatinib remains a formulation-sensitive compound because of low aqueous solubility and strong dependence of absorption on gastrointestinal conditions.

Lapatinib has a molecular weight of approximately 581.06 g/mol as the ditosylate monohydrate salt. The active moiety is a hydrophobic, weakly basic small molecule with limited intrinsic solubility.[2]

What are the principal formulation constraints?

The main constraints are:

1. Low and variable dissolution.
2. Clinically significant food effects.
3. Sensitivity to gastric pH and acid-reducing agents.
4. High daily tablet count.
5. Potentially narrow commercial tolerance for bioavailability differences because exposure is linked to toxicity, including diarrhea, rash and hepatotoxicity.

The FDA label instructs patients to take lapatinib at least one hour before or one hour after food. Food can materially increase lapatinib exposure, and strong CYP3A4 inhibitors or inducers can further alter systemic concentrations.[1]

How do excipients affect lapatinib bioavailability?

Excipients can affect lapatinib through wetting, disintegration, particle deagglomeration, microenvironmental pH, precipitation after dissolution, and gastrointestinal transit.

Disintegrants and wetting agents

Sodium starch glycolate supports rapid tablet breakup. A generic developer could evaluate crospovidone or croscarmellose sodium as alternatives, but substitution is not automatically neutral. Different swelling mechanisms and particle sizes can change:

• Tablet disintegration time
• Granule porosity
• Dissolution rate
• Compression force
• Ejection force
• Stability under humidity

Surfactants such as sodium lauryl sulfate, poloxamers or polysorbates may improve wetting, but they can create risks involving assay interference, tablet lubrication, oxidation, taste and gastrointestinal tolerability. Surfactant selection should be driven by discriminatory dissolution testing rather than by dissolution speed alone.

Microenvironmental pH modifiers

Because lapatinib is a weakly basic compound, alkaline or acidic microenvironments can alter apparent solubility and precipitation behavior. Excipients such as citric acid, fumaric acid, succinic acid or alkaline carbonates may be evaluated in an enabling formulation, but the target is not simply maximum dissolution in a single medium.

A practical development program should measure:

• Intrinsic dissolution
• pH-solubility profiles
• Supersaturation and precipitation
• Dissolution across pH 1.2, 4.5 and 6.8
• Dissolution in biorelevant media
• Compatibility with proton-pump inhibitors and H2 antagonists

The preferred excipient system is one that provides reproducible exposure across physiologically relevant conditions without creating an exaggerated food effect.

Lubricants

Magnesium stearate is effective at low concentrations but can create hydrophobic coating of particles when overmixed. That can delay wetting and dissolution. A generic formulation may obtain a measurable performance advantage by controlling:

• Lubricant concentration
• Mixing time
• Shear history
• Granule moisture
• Compression force

Sodium stearyl fumarate is a potential alternative lubricant where dissolution sensitivity or over-lubrication is a concern. The commercial value is usually manufacturing consistency rather than a new clinical claim.

What excipient strategies are available for lapatinib?

Strategy 1: Conventional immediate-release tablet

This is the lowest-risk pathway for an ANDA applicant. The developer can retain a qualitatively similar excipient system while optimizing quantities and process conditions.

Potential advantages include:

• Lower development cost
• Familiar tablet manufacturing
• Easier scale-up
• Lower regulatory complexity
• Compatibility with generic substitution

The main commercial challenge is that conventional tablets must match the reference product closely enough in dissolution and bioequivalence while competing against established generic suppliers.

Strategy 2: Amorphous solid dispersion

An amorphous solid dispersion can increase apparent solubility and dissolution by reducing crystallinity and improving drug-polymer interactions. Candidate polymers may include:

• Hydroxypropyl methylcellulose acetate succinate
• Hydroxypropyl methylcellulose
• Polyvinylpyrrolidone
• Vinylpyrrolidone-vinyl acetate copolymers
• Soluplus-type graft copolymers

The key risks are recrystallization, moisture uptake, residual solvent, melt-processing degradation and physical instability during storage.

For lapatinib, an amorphous dispersion is more likely to support a differentiated 505(b)(2) product or a life-cycle management program than a standard ANDA, particularly if it can reduce food dependence or enable a lower tablet burden.

Strategy 3: Lipid-based formulation

Self-emulsifying drug delivery systems and other lipid-based systems can improve solubilization of hydrophobic compounds. Candidate vehicles include medium-chain triglycerides, long-chain lipids, mono- and diglycerides, and nonionic surfactants.

Potential benefits are:

• Higher apparent solubility
• Reduced precipitation after dilution
• Improved absorption consistency
• Possible reduction in food-related variability

Risks include capsule-fill limitations, liquid handling, oxidation, excipient tolerability, precipitation in intestinal fluid and more complex manufacturing. A lipid formulation may be commercially attractive if it produces a clinically meaningful reduction in food effect or improves administration for patients who cannot reliably follow fasting instructions.

Strategy 4: Nanocrystal or nanosuspension technology

Particle-size reduction can increase surface area and dissolution rate without requiring a large excipient load. Stabilizers may include povidone, hydroxypropyl cellulose, poloxamers or surfactant combinations.

Nanocrystals may fit a tablet, capsule or oral suspension platform. The main technical risks are aggregation, Ostwald ripening, residual solvent or milling media, and scale-up control. The value proposition is strongest where dissolution is the rate-limiting step and the product can demonstrate consistent exposure with a simpler dosage regimen.

Strategy 5: Cyclodextrin or host-guest solubilization

Cyclodextrins can improve aqueous solubility, but the feasibility of a high-dose lapatinib product depends on complexation efficiency and excipient burden. Because daily doses can reach 1,250 to 1,500 mg, a cyclodextrin-heavy oral formulation may become too large or expensive unless the complex substantially improves drug loading.

Cyclodextrin systems are more plausible for liquid, pediatric or specialty dosage forms than for a low-cost adult tablet.

Strategy 6: Multiparticulate or sprinkle formulation

A multiparticulate product could address swallowing difficulty and enable dose flexibility. It would require control of particle size, dose uniformity, coating integrity, taste and gastric release.

This is a potential 505(b)(2) opportunity rather than a straightforward generic opportunity. The commercial case depends on demonstrating a patient-use benefit, such as administration through enteral feeding tubes or improved swallowing for oncology patients.

What patents protect lapatinib formulations?

Lapatinib has historically been protected by compound, salt, formulation and method-of-use rights associated with GlaxoSmithKline. The principal commercial product is Tykerb, also marketed as Tyverb in some jurisdictions. The original lapatinib product patents have reached or approached the end of their effective commercial life in major markets, and generic lapatinib products have entered the U.S. market.

The relevant intellectual-property categories are:

IP category	Commercial relevance
Lapatinib compound patents	Core exclusivity; generally expired or late-life in major markets
Ditosylate salt and crystalline-form claims	May affect API manufacture and solid-state selection
Tablet formulation claims	Potential relevance to specific excipient ratios or manufacturing steps
Combination therapy claims	Historically important for lapatinib with capecitabine or endocrine therapy
Method-of-use claims	May remain relevant in selected jurisdictions if enforceable
Enabling formulation claims	Relevant to new dispersions, lipid systems, nanocrystals or pediatric products

A developer should separate expired core rights from later-filed formulation or use patents. A later patent covering an amorphous dispersion, particle-size range, excipient ratio or dosing method may create a product-specific barrier even when the original compound patent has expired.

What is the Orange Book status of lapatinib?

Lapatinib is an approved small-molecule drug listed in FDA drug databases, and its generic pathway is an ANDA rather than a biosimilar application. The applicable regulatory analysis should review the current Orange Book for:

• Listed patents associated with the relevant reference NDA
• Patent expiration dates
• Pediatric exclusivity adjustments
• Approved dosage forms and strengths
• Whether listed patents remain active or have expired

Orange Book status can change through patent expiration, delisting, litigation outcomes and regulatory updates. Applicants must evaluate the live listing at the time of filing rather than rely on historical Tykerb patent summaries.[3]

When does lapatinib lose exclusivity?

Lapatinib’s market exclusivity is determined by the interaction of regulatory exclusivity and patent rights. The core product has been commercially available for many years, and generic competition has emerged in the United States.

Milestone	Date or status
FDA approval of Tykerb	March 13, 2007
Primary indication	HER2-positive advanced or metastatic breast cancer
FDA approval of combination with capecitabine	2007
FDA approval with letrozole for HR-positive, HER2-positive metastatic breast cancer	2010
Current market position	Mature small-molecule product with generic competition
Biosimilar exclusivity	Not applicable

The six-month pediatric exclusivity period associated with the reference product affected the timing of certain U.S. regulatory rights but does not create a current barrier to generic development.[1,3]

Which companies are challenging lapatinib exclusivity?

Generic-drug companies have pursued lapatinib tablets through the ANDA pathway. Public FDA sources should be used to identify current approved applicants, marketing status and tentative approvals. The competitive field is generally made up of manufacturers that can supply lapatinib ditosylate tablets at low cost and satisfy bioequivalence requirements.

The more important competitive distinction is likely to be manufacturing economics:

• Direct compression versus wet granulation
• API particle-size control
• Domestic versus offshore API supply
• Yield and tablet reject rates
• Stability-packaging requirements
• Ability to supply multiple 250 mg tablet volumes

A company with a conventional bioequivalent tablet may compete on price. A company with a clinically differentiated formulation must compete on evidence, physician adoption and reimbursement.

What generic entry risks exist for lapatinib?

Paragraph IV challenges

A Paragraph IV certification may be relevant where an applicant believes a listed patent is invalid, unenforceable or not infringed. For lapatinib, the commercial value of a Paragraph IV strategy depends on whether any unexpired Orange Book patent remains material to the intended product.

The main risks include:

• A formulation patent covering the proposed excipient system
• A method-of-use patent covering a planned labeled indication
• A salt or solid-state patent affecting the API
• A 30-month stay following patent litigation
• At-risk launch exposure after approval
• Damages or injunctive relief if the patent holder prevails

A simple immediate-release tablet with a composition materially different from any surviving formulation claim generally has a cleaner design-around path than an enabling formulation that intentionally replicates a patented dispersion or delivery system.

Litigation and settlement exposure

Lapatinib litigation risk is product-specific. A generic applicant must review ANDA notices, district-court complaints, Federal Circuit decisions, consent judgments and any settlement terms tied to the relevant Orange Book patent.

Settlement agreements can affect:

• Earliest authorized generic entry
• Launch dates
• Supply or licensing obligations
• Authorized-generic arrangements
• Restrictions on pediatric or combination indications

A patent settlement that permits an early launch may reduce the value of a Paragraph IV challenge for later entrants.

How strong is the lapatinib patent estate?

The core estate is weaker than it was during the branded exclusivity period because lapatinib has been marketed since 2007 and generic competition is established. The strongest remaining barriers, where present, are likely to be narrow and product-specific rather than broad compound protection.

Estate component	Relative strategic strength
Original chemical entity protection	Low after expiry
Lapatinib ditosylate salt	Low to moderate, depending on jurisdiction and claim scope
Reference tablet composition	Low to moderate
New amorphous or nanocrystalline forms	Moderate to strong if valid and clinically useful
Food-effect reduction claims	Potentially strong if supported by clinical data
Pediatric or feeding-tube formulation	Potentially strong for a differentiated product
Combination-treatment methods	Indication- and jurisdiction-specific

The strongest commercial IP opportunity is a formulation that solves a documented clinical problem and generates a patentable product profile. Excipient substitution alone rarely creates durable exclusivity unless it produces a novel composition with demonstrated performance.

What commercial opportunities exist for lapatinib excipients?

Low-cost generic tablet supply

The largest near-term opportunity is efficient manufacture of a bioequivalent 250 mg tablet. High-value formulation work may include:

• Lower-cost direct compression
• Improved granule flow
• Reduced magnesium stearate sensitivity
• Faster scale-up
• Reduced tablet weight
• Stable packaging in high-volume oncology supply

This market is competitive and price-sensitive. The principal buyers are generic oncology suppliers, wholesalers and public-health procurement systems.

Differentiated oral delivery

A formulation that reduces fasting restrictions, lowers food-effect variability or decreases pill burden could support a specialty product. Such a product would need clinical evidence because the current label specifically controls administration around meals.[1]

Potential product concepts include:

• Once-daily high-dose tablet with fewer units
• Food-effect-mitigating formulation
• Sprinkle formulation for swallowing-impaired patients
• Enteral-tube-compatible product
• Oral suspension for dose flexibility
• Fixed-dose combination with an established partner where legally and clinically appropriate

Excipient suppliers and formulation-platform companies

Excipient companies may target lapatinib through platform technologies rather than drug-specific sales. Attractive platforms include:

• Spray-dried dispersion systems
• Co-processed excipients for direct compression
• Lipid-based solubilization systems
• Nanocrystal stabilizer packages
• Moisture-control and protective film coatings
• Taste-masking systems for pediatric or liquid products

The commercial model may involve formulation licensing, development services, supply agreements or a co-development arrangement with a generic or specialty pharmaceutical company.

How does lapatinib compare with other HER2-directed drugs?

Lapatinib is a small-molecule oral tyrosine kinase inhibitor. It does not face biosimilar substitution in the same way as trastuzumab, pertuzumab or other biologic HER2 therapies.

Product type	Example	Regulatory competition
Oral small molecule	Lapatinib	ANDA generics
Monoclonal antibody	Trastuzumab	Biosimilars
Antibody-drug conjugate	Trastuzumab emtansine	Complex biologic competition
Oral kinase inhibitor	Neratinib, tucatinib	Small-molecule patent and generic risk

Lapatinib’s formulation opportunity is greater than its biosimilar opportunity because the drug is chemically defined and can be developed through conventional generic or 505(b)(2) pathways. Its commercial disadvantage is the high tablet burden and clinically important food and drug-interaction management.

What manufacturing and IP barriers affect lapatinib?

Manufacturing barriers are moderate. Lapatinib does not require sterile production, cell culture or biologic comparability studies. The main technical barriers are API quality, solid-state control, dissolution reproducibility and scale-up.

A robust control strategy should address:

• Salt form and hydration state
• API particle-size distribution
• Polymorph or amorphous content
• Blend uniformity
• Granule moisture
• Lubrication time
• Compression force
• Dissolution across pH conditions
• Long-term and accelerated stability
• Container-closure moisture protection

For an enabling formulation, the IP strategy should claim the composition, process, solid state, dissolution profile and clinical use where supported. Broad claims based only on a familiar excipient combination are vulnerable to prior art and design-around.

What is the best excipient strategy for a lapatinib developer?

For an ANDA applicant, the preferred approach is a Q1/Q2-compatible immediate-release tablet using a conventional diluent-binder-disintegrant-lubricant system, with intensive control of API particle size, lubrication and dissolution.

For a 505(b)(2) developer, the strongest opportunity is a formulation that demonstrates one of four measurable benefits:

1. Lower food-effect variability.
2. Reduced dosing burden.
3. Improved administration for swallowing-impaired patients.
4. More consistent exposure with acid-reducing therapy.

A dispersion, lipid-based system or nanocrystal formulation should not be commercialized solely on faster dissolution. The product must connect formulation performance to a clinically relevant advantage and a defensible patent position.

Key Takeaways

• Lapatinib is a poorly soluble, high-dose oral kinase inhibitor with meaningful food and pH-related formulation sensitivity.
• Tykerb uses a conventional immediate-release tablet containing lapatinib ditosylate monohydrate, microcrystalline cellulose, povidone, sodium starch glycolate and magnesium stearate.
• The generic opportunity is primarily an ANDA opportunity, not a biosimilar opportunity.
• Conventional tablets offer the lowest regulatory and manufacturing risk but face intense price competition.
• Amorphous dispersions, lipid systems and nanocrystals may support differentiated products if they reduce food effects, tablet burden or administration barriers.
• The original lapatinib exclusivity position has matured; surviving barriers are more likely to involve narrow formulation, solid-state or method-of-use claims.
• Excipient substitution alone is unlikely to create durable commercial exclusivity.
• The most valuable formulation program links excipient selection to a clinical outcome and a patentable product profile.

FAQs

Can lapatinib be formulated as a liquid oral product?

Yes. A liquid or suspension product is technically feasible, but solubility, physical stability, taste, dose uniformity and preservative compatibility must be controlled. The high daily dose can make a true solution impractical, increasing the attractiveness of a suspension or nanosuspension.

Which excipients are most likely to improve lapatinib dissolution?

Polymeric dispersion carriers, surfactants, lipid excipients, particle-size-reduction stabilizers and selected pH modifiers are the principal options. The best choice depends on precipitation behavior and biorelevant dissolution, not on dissolution rate in water alone.

Does lapatinib have biosimilar competition?

No. Lapatinib is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways such as ANDAs, not through the FDA biosimilar pathway.

Could a lower tablet count create new lapatinib exclusivity?

A lower tablet count alone is unlikely to create strong exclusivity. A higher-strength or modified formulation may support patent protection only if it has a novel composition, manufacturing process or clinically meaningful pharmacokinetic advantage.

Are food-effect-reducing lapatinib formulations commercially attractive?

Yes, if clinical studies show materially more consistent exposure or easier administration. The opportunity is strongest where the formulation can support a differentiated label, reimbursement position and enforceable composition or use claims.

References

1. U.S. Food and Drug Administration. (2024). Tykerb (lapatinib) tablets: Prescribing information.
2. National Center for Biotechnology Information. (2024). PubChem compound summary: Lapatinib. PubChem.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. European Medicines Agency. (2008). Tyverb: European public assessment report.
5. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.